Please assess the completion status of the following clinical trial:

Trial Title: Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants must be ambulatory.~* Participants must meet the following core clinical criteria as determined by the Investigator:~Prodromal Alzheimer's Disease (AD) (all of the criteria must apply):~* Mini Mental State Examination (MMSE) scores between 24-30 (inclusive)~* a spontaneous memory complaint~* objective memory loss defined as a free recall score of ≤27 on the Free and Cued Selective Reminding Test (FCSRT)~* a global Clinical Dementia Rating Scale (CDR) score of 0.5~* absence of significant levels of impairment in other cognitive domains~* essentially preserved activities of daily living, and an absence of dementia. OR~Mild Alzheimer's Disease (AD) criteria (all criteria must apply):~* Mini Mental State Examination (MMSE) scores between 20-26 (inclusive)~* a global Clinical Dementia Rating Scale (CDR) of 0.5 or 1.0~* meeting the National Institute on Aging-Alzheimer's Association core clinical criteria for probable AD.~* Participants must have a positive florbetapir positron emission tomography (PET) amyloid scan.~* Participants must consent to apolipoprotein E (ApoE) genotyping.~* Apart from clinical diagnosis of Alzheimer's Disease (AD), participant must be in good health.~* Must have a reliable informant or caregiver.~Key Exclusion Criteria:~* Any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the participant's cognitive impairment.~* Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year.~* Clinically significant psychiatric illness in past 6 months.~* Seizure in the past 3 years.~* Poorly controlled diabetes mellitus.~* History of unstable angina, myocardial infarction, chronic heart failure, or clinical significant conduction abnormalities within 1 year prior to Screening.~* Indication of impaired renal or liver function.~* Have human immunodeficiency virus (HIV) infection.~* Have a significant systematic illness or infection in past 30 days.~* Brain MRI showing evidence of acute or sub-acute micro or macrohemorrhage, greater than 4 microhemorrhages, cortical infarct or greater than one 1 lunar infarct.~* Any contraindications to brain MRI or positron emission tomography (PET) scans.~* Negative positron emission tomography (PET) scan with any amyloid-targeting ligand within 48 weeks of Screening.~* Clinically significant 12-lead electrocardiogram (ECG) abnormalities.~* Alcohol or substance abuse in past 1 year.~* Taking blood thinners (except for aspirin at a prophylactic dose or less)~* Have changes in medications or doses of medication in past 4 weeks.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Low-dose #1 Aducanumab (Type: EXPERIMENTAL): Intravenous doses of low-dose level #1 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
- Low-dose #2 Aducanumab (Type: EXPERIMENTAL): Intravenous doses of low-dose level #2 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
- Placebo (low dose group) (Type: PLACEBO_COMPARATOR): Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
- Mid-dose Aducanumab (Type: EXPERIMENTAL): Intravenous doses of mid-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
- Placebo (mid dose group) (Type: PLACEBO_COMPARATOR): Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
- High-dose Aducanumab (Type: EXPERIMENTAL): Intravenous doses of high-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
- Placebo (high dose group) (Type: PLACEBO_COMPARATOR): Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
- Aducanumab Titration (Type: EXPERIMENTAL): Intravenous doses of Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
- Placebo (Titration Group) (Type: PLACEBO_COMPARATOR): Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).